News

Rutgers University1d
FDA Clears First Blood Test for Alzheimer’s Diagnosis, a “Turning Point” in Early Detection
Unlike expensive positron emission tomography (PET) scans or invasive lumbar punctures, the new blood test measures the ratio ...
Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
New program combines IV-delivered TRACER™ capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 ...
Voyager Therapeutics, Inc.: Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
New program combines IV-delivered TRACER capsid with bifunctional payload to silence APOE in carriers of the high-risk APOE4 variant while delivering the protective APOE2 variant - - Voyager's wholly- ...
Nasdaq24d
Contineum Therapeutics Provides Update on Phase 1b Positron Emission ...
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 Published Jun 25, 2025 8:15am EDT ...
New blood biomarker predicts progression of Alzheimer's disease even in its earliest stages
A team of researchers at the Sant Pau Research Institute (IR Sant Pau) has demonstrated that the plasma biomarker p-tau217, ...